CSF2 and melanoma: One oncolytic herpesvirus therapy, Talimogene laherparevec (T-VEC; also known as OncoVEX^GM-CSF and IMLYGICTM), has received approval from the United States Food and Drug Administration (FDA) for treatment of inoperable melanoma, and investigations for its use in a wide variety of malignant conditions are underway (15).